UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancer treatments, has announced its participation in two major investor conferences in February 2025.
The company will present at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, at 10:30 AM ET in New York, NY, featuring both a presentation and one-on-one investor meetings. Additionally, UroGen will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 1:20 PM ET in a virtual format.
Both conference presentations will be webcast and available on UroGen's Investor Relations website, with replays accessible for approximately 90 days following the events.
UroGen Pharma (Nasdaq: URGN), un'azienda biotecnologica focalizzata sui trattamenti per il cancro uroteliale e di specialità, ha annunciato la sua partecipazione a due importanti conferenze per investitori a febbraio 2025.
L'azienda presenterà al Guggenheim Securities SMID Cap Biotech Conference il 5 febbraio 2025, alle 10:30 AM ET a New York, NY, con una presentazione e incontri individuali con gli investitori. Inoltre, UroGen parteciperà al Oppenheimer 35th Annual Healthcare Life Sciences Conference l'11 febbraio 2025, alle 1:20 PM ET in formato virtuale.
Entrambi gli eventi saranno trasmessi in diretta e disponibili sul sito delle Relazioni con gli Investitori di UroGen, con registrazioni accessibili per circa 90 giorni dopo gli eventi.
UroGen Pharma (Nasdaq: URGN), una compañía biotecnológica enfocada en tratamientos para cáncer urotelial y de especialidad, ha anunciado su participación en dos importantes conferencias para inversores en febrero de 2025.
La compañía presentará en la Guggenheim Securities SMID Cap Biotech Conference el 5 de febrero de 2025, a las 10:30 AM ET en Nueva York, NY, con una presentación y reuniones individuales con inversores. Además, UroGen participará en la Oppenheimer 35th Annual Healthcare Life Sciences Conference el 11 de febrero de 2025, a la 1:20 PM ET en formato virtual.
Ambas presentaciones de la conferencia serán transmitidas por webcast y estarán disponibles en el sitio web de Relaciones con Inversores de UroGen, con repeticiones accesibles durante aproximadamente 90 días después de los eventos.
UroGen Pharma (Nasdaq: URGN)는 상피세포 및 특수 암 치료에 중점을 둔 생명공학 회사로, 2025년 2월에 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다.
회사는 2025년 2월 5일 오전 10시 30분 ET에 뉴욕, NY에서 열리는 Guggenheim Securities SMID Cap Biotech Conference에서 발표를 하고, 개별 투자자 미팅도 진행합니다. 또한, UroGen은 2025년 2월 11일 오후 1시 20분 ET에 가상 형식으로 Oppenheimer 35th Annual Healthcare Life Sciences Conference에 참여할 예정입니다.
양 회의의 발표는 웹캐스트로 방송되며, UroGen의 투자자 관계 웹사이트에서 약 90일 동안 다시 볼 수 있습니다.
UroGen Pharma (Nasdaq: URGN), une entreprise biopharmaceutique spécialisée dans les traitements des cancers urotéliaux et des spécialités, a annoncé sa participation à deux grandes conférences d'investisseurs en février 2025.
L'entreprise présentera à la Guggenheim Securities SMID Cap Biotech Conference le 5 février 2025 à 10h30 ET à New York, NY, avec à la fois une présentation et des réunions individuelles avec des investisseurs. De plus, UroGen participera à la Oppenheimer 35th Annual Healthcare Life Sciences Conference le 11 février 2025 à 13h20 ET sous un format virtuel.
Les présentations de ces deux conférences seront diffusées en direct et disponibles sur le site des Relations avec les Investisseurs d'UroGen, avec des rediffusions accessibles pendant environ 90 jours après les événements.
UroGen Pharma (Nasdaq: URGN), ein biopharmazeutisches Unternehmen, das sich auf uroteliale und spezielle Krebsbehandlungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Februar 2025 bekannt gegeben.
Das Unternehmen wird am 5. Februar 2025 um 10:30 Uhr ET in New York, NY, auf der Guggenheim Securities SMID Cap Biotech Conference präsentieren, einschließlich einer Präsentation und persönlichen Treffen mit Investoren. Darüber hinaus wird UroGen an der Oppenheimer 35th Annual Healthcare Life Sciences Conference am 11. Februar 2025 um 13:20 Uhr ET in virtueller Form teilnehmen.
Beide Konferenzpräsentationen werden im Webcast übertragen und sind auf der Investor Relations-Website von UroGen verfügbar, mit Wiederholungen, die etwa 90 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
Guggenheim Securities SMID Cap Biotech Conference
Date / Time: |
February 5, 2025 at 10:30 AM ET |
||
Format: |
Presentation and 1x1 investor meetings |
||
Location: |
|
||
Webcast Link: |
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date / Time: |
February 11, 2025 at 1:20 PM ET |
||
Format: |
Presentation and 1x1 investor meetings |
||
Location: |
Virtual |
||
Webcast Link: |
Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130241788/en/
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When is UroGen Pharma (URGN) presenting at the Guggenheim Securities Conference in 2025?
What is the format of URGN's presentation at the Oppenheimer Healthcare Conference 2025?
How long will the webcasts of URGN's February 2025 investor conferences be available?
Which investor conferences is URGN attending in February 2025?
